

Module: QScript Learning –Opioid rotation

Course: PRESCRIBER AND DISPENSER TRAINING

Suggested Citation:

Insight: Centre for AOD Training and Workforce Development. Opioid rotation. QScript Learning. Prescriber and dispenser training [Internet]. 2023. Available from: <https://insight.qld.edu.au/training/elearning>.

1. Royal Australian College of General Practitioners. Prescribing drugs of dependence in general practice - Part C1: Opioids [cited 2019 Mar 21]. Available from: <https://www.racgp.org.au/clinical-resources/clinical-guidelines/key-racgp-guidelines/view-all-racgp-guidelines/drugs-of-dependence>.
2. Maher E, Nielsen S, Summers R, Wood P. Core competencies for Australian pharmacists when supplying prescribed opioids: a modified Delphi study. International Journal of Clinical Pharmacy. 2020.doi: 10.1007/s11096-020-01060-x
3. Treillet E, Laurent S, Hadjiat Y. Practical management of opioid rotation and equianalgesia. Journal of Pain Research. 2018;11:2587-601.doi: 10.2147/JPR.S170269
4. Intermountain Healthcare. Prescribing opioid for chronic non-cancer pain [cited. Available from: https://intermountainphysician.org/Documents/OpioidPrescribing_Chronic%20Pain.pdf.
5. Smith HS, Peppin JF. Toward a systematic approach to opioid rotation. Journal of Pain Research. 2014;7:589-608.doi: 10.2147/JPR.S55782
6. Nalamachu S. Opioid rotation with extended-release opioids: where should we begin? Int J Gen Med. 2012;5:11-7.doi: 10.2147/IJGM.S24287
7. Insight Centre for AOD Training and Workforce Development, QScript Learning. Tony Hall - why consider opioid rotation? [cited 2020 30 Jun]. Available from: <https://youtu.be/l-OWFVGIG-c>.
8. Webster LR, Fine PG. Review and critique of opioid rotation practices and associated risks of toxicity. Pain Med. 2012;13(4):562-70.doi: 10.1111/j.1526-4637.2012.01357.x
9. Armstrong F, Arunogiri S, Frei MY, Lubman DI. The six Rs of managing high-risk opioid prescribing. Australian journal of general practice. 2020;49(3):116.doi: 10.31128/AJGP-06-19-4967
10. Royal Australian College of General Practitioners. Prescribing drugs of dependence in general practice, Part C2: The role of opioids in pain management [cited 2019 Mar 21]. Available from: <https://www.racgp.org.au/clinical-resources/clinical-guidelines/key-racgp-guidelines/view-all-racgp-guidelines/drugs-of-dependence>.
11. Pham PC, Khaing K, Sievers TM, Pham PM, Miller JM, Pham SV, et al. 2017 update on pain management in patients with chronic kidney disease. Clin Kidney J. 2017;10(5):688-97.doi: 10.1093/ckj/sfx080
12. Australian Commission on Safety and Quality in Health Care. High risk medicines resources [cited 2021 24 Feb]. Available from: <https://www.safetyandquality.gov.au/our-work/medication-safety/high-risk-medicines/high-risk-medicines-resources>.
13. Insight Centre for AOD Training and Workforce Development, QScript Learning. Tony Hall - equianalgesic opioid doses: "A clinical estimate" [cited 2020 30 June]. Available from: <https://youtu.be/BPFlaDUotnQ>.
14. Insight Centre for AOD Training and Workforce Development, QScript Learning. Tony Hall - inter-patient variability [cited 2020 30 Jun]. Available from: <https://youtu.be/4yVh2cCHkhc>.
15. Faculty of Pain Medicine ANZCA. PM01 (Appendix 1) - Quick reference recommendations for conduct of an opioid trial on chronic non-cancer pain [cited 2020 14 Apr]. Available from: <https://www.anzca.edu.au/safety-advocacy/standards-of-practice/policies,-statements,-and-guidelines>.
16. Drewes AM, Jensen RD, Nielsen LM, Dronney J, Christrup LL, Arendt-Nielsen L, et al. Differences between opioids: pharmacological, experimental, clinical and economical perspectives. British journal of clinical pharmacology. 2013;75(1):60-78.doi: 10.1111/j.1365-2125.2012.04317.x
17. Collins S, Faura C, Moore RA, McQuay H. Peak plasma concentrations after oral morphine: a systematic review. Journal of Pain Symptom Manage. 1998;16(6):388-402.doi: 10.1016/S0885-3924(98)00094-3

18. Snyder B. Revisiting old friends: Update on opioid pharmacology. *Australian Prescriber*. 2014;37(2):56-60.doi: 10.18773/austprescr.2014.021
19. MS Contin [cited 2020 16 Jul]. Available from: <http://www.mims.com.au>.
20. Due MR, Piekarcz AD, Wilson N, Feldman P, Ripsch MS, Chavez S, et al. Neuroexcitatory effects of morphine-3-glucuronide are dependent on Toll-like receptor 4 signaling. *Journal of Neuroinflammation*. 2012;9(1):200.doi: 10.1186/1742-2094-9-200
21. Lee K, Ganta N, Horton J, Chai E. Evidence for morphine or hydromorphone-induced neurotoxicity in renal impairment: a systematic review (S705). *Journal of Pain and Symptom Management*. 2017;53(2):412-.doi: 10.1016/j.jpainsymman.2016.12.215
22. Noble M, Treadwell JR, Tregear SJ, Coates VH, Wiffen PJ, Akafomo C, et al. Long-term opioid management for chronic noncancer pain. *Cochrane Database of Systematic Reviews*. 2010(1).doi: 10.1002/14651858.CD006605.pub2
23. Therapeutic Goods Administration. Oxycotin® (Oxycodone hydrochloride modified release tablets) [cited 2020 15 Jul]. Available from: <https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2013-PI-02353-1>.
24. Insight Centre for AOD Training and Workforce Development, QScript Learning. Withdrawal management when tapering - Lily Taylor [cited 2020 30 Jun]. Available from: <https://youtu.be/SMhNtNMd3wI>.
25. Pathan H, Williams J. Basic opioid pharmacology: An update. *British Journal of Pain*. 2012;6(1):11-6.doi: 10.1177/2049463712438493
26. Dilaudid® tablets (2 mg, 4 mg and 8 mg), Dilaudid® oral liquid (1 mg/mL) [cited 2020 15 Jul]. Available from: <https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2017-PI-01353-1>.
27. Therapeutic Goods Administration. Jurnista®(Hydromorphone hydrochloride prolonged-release tablets). Australian Product Information. 2020 [cited 2020 15 Jul]; p.]^pp.]. Available from: <https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2010-PI-04176-3>.
28. Mu A, Weinberg E, Moulin DE, Clarke H. Pharmacologic management of chronic neuropathic pain: Review of the Canadian Pain Society consensus statement. *Canadian family physician Medecin de famille canadien*. 2017 [cited 2020 5 Jan]; 63(11):[844-52 p.]^pp.]. Available from: <https://pubmed.ncbi.nlm.nih.gov/29138154/>.
29. Shah JC, Mason WD. Plasma codeine and morphine concentrations after a single oral dose of codeine phosphate. *J Clin Pharmacol*. 1990;30(8):764-6.doi: 10.1002/j.1552-4604.1990.tb03641.x
30. Trescot AM, Datta S, Lee M, Hansen H. Opioid pharmacology. *Pain physician*. 2008 Mar [cited 2019 27 June]; 11(2 Suppl):[S133-53 p.]^pp.]. Available from: <https://europepmc.org/abstract/med/18443637>.
31. Johnson JL, Rolan PE, Johnson ME, Bobrovskaya L, Williams DB, Johnson K, et al. Codeine-induced hyperalgesia and allodynia: investigating the role of glial activation. *Transl Psychiatry*. 2014;4(11):e482-e.doi: 10.1038/tp.2014.121
32. Flanagan RJ, Johnston A, White AS, Crome P. Pharmacokinetics of dextropropoxyphene and nordextropropoxyphene in young and elderly volunteers after single and multiple dextropropoxyphene dosage. *British journal of clinical pharmacology*. 1989;28(4):463-9.doi: 10.1111/j.1365-2125.1989.tb03527.x
33. Barkin RL, Barkin SJ, Barkin DS. Propoxyphene (dextropropoxyphene): a critical review of a weak opioid analgesic that should remain in antiquity. *American journal of therapeutics*. 2006;13(6):534-42.doi: 10.1097/01.mjt.0000253850.86480.fb
34. Collins SL, Edwards JE, Moore RA, McQuay HJ. Single dose dextropropoxyphene, alone and with paracetamol (acetaminophen), for postoperative pain. *The Cochrane database of systematic reviews*. 2000;1999(2):Cd001440.doi: 10.1002/14651858.Cd001440
35. Therapeutic Goods Administration. APO-Tramadol. Australian Product Information. 2020 [cited 2020 16 Jul]; p.]^pp.]. Available from: <https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2011-PI-02025-3>.
36. Barakat A. Revisiting tramadol: a multi-modal agent for pain management. *CNS Drugs*. 2019;33(5):481-501.doi: 10.1007/s40263-019-00623-5
37. Therapeutic Goods Administration. APO-Tramadol SR, 100mg, 150mg and 200mg modified release tablets. Australian Product Information. 2020 [cited 2020 16 Jul]; p.]^pp.]. Available from: <https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2010-PI-01251-3>.
38. Beakley BD, Kaye A, Kaye AD. Tramadol, pharmacology, side effects, and serotonin syndrome: a review. *Pain physician*. 2015 [cited 2020 10 Jan]; 18(4):[395-400 p.]^pp.]. Available from: <https://pubmed.ncbi.nlm.nih.gov/26218943/>.

39. Kaye K, MacDonell D. Trouble with tramadol. *Australian Prescriber*. 2004;27(2):26-7.doi: 10.18773/austprescr.2004.023
40. Therapeutic Goods Administration. Palexia® IR (tapentadol (as hydrochloride)) immediate release, tablets. Australian Product Information. 2020 [cited 2020 16 Jul]; p.]^pp.]. Available from: <https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2017-PI-01561-1>.
41. Therapeutic Goods Administration. Australian product information – Palexia® SR (tapentadol (as hydrochloride)) sustained release tablets. Australian Product Information. 2020 [cited 2020 16 Jul]; p.]^pp.]. Available from: <https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2017-PI-01558-1>.
42. Langford RM, Knaggs R, Farquhar-Smith P, Dickenson AH. Is tapentadol different from classical opioids? A review of the evidence. *British journal of pain*. 2016;10(4):217-21.doi: 10.1177/2049463716657363
43. Niesters M, Proto PL, Aarts L, Sarton EY, Drewes AM, Dahan A. Tapentadol potentiates descending pain inhibition in chronic pain patients with diabetic polyneuropathy. *BJA: British Journal of Anaesthesia*. 2014;113(1):148-56.doi: 10.1093/bja/aeu056
44. Channell J, Schug S. Toxicity of tapentadol: a systematic review. *Pain Manag*. 2018;8.doi: 10.2217/pmt-2018-0027
45. Therapeutic Goods Administration. Physeptone (methadone hydrochloride) tablets & injection. Australian Product Information. 2020 [cited 2020 16 Jul]; p.]^pp.]. Available from: <https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2011-PI-01978-3>.
46. Eap CB, Buclin T, Baumann P. Interindividual variability of the clinical pharmacokinetics of methadone. *Clinical Pharmacokinetics*. 2002;41(14):1153-93.doi: 10.2165/00003088-200241140-00003
47. Morgan RW, Nicholson KL. Characterization of the antinociceptive effects of the individual isomers of methadone after acute and chronic administrations. *Behavioural pharmacology*. 2011;22(5-6):548-57.doi: 10.1097/FBP.0b013e328349ab0d
48. Palat G, Chary S. Practical guide for using methadone in pain and palliative care practice. *Indian journal of palliative care*. 2018;24(Suppl 1):S21-S9.doi: 10.4103/IJPC.IJPC_186_17
49. Gowing L, Ali R, Dunlop A, Farrell M, Lintzeris N. National guidelines for medication-assisted treatment of opioid dependence. Canberra: Commonwealth of Australia Department of Health; 2014.
50. Therapeutic Goods Administration. Suboxone® film (buprenorphine/naloxone). Australian Product Information. 2019 [cited 2020 16 Jul]; p.]^pp.]. Available from: <https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2011-PI-01894-3>.
51. Trivedi M, Shaikh S, Gwinnutt C. Pharmacology of opioids. Update in Anaesthesia. 2008 [cited 2019 12 Mar]; 24(2):[118-24 p.]^pp.]. Available from: https://www.wfsahq.org/components/com_virtual_library/media/c96525cdf115fe1022c50fabb814b76a-Opioid-Pharmacology--Update-24-2-2008-.pdf.
52. Webster L, Gudín J, Raffa RB, Kuchera J, Rauck R, Fudin J, et al. Understanding buprenorphine for use in chronic pain: expert opinion. *Pain Medicine*. 2020;21(4):714-23.doi: 10.1093/pm/pnz356
53. Kress HG. Clinical update on the pharmacology, efficacy and safety of transdermal buprenorphine. *European Journal of Pain*. 2009;13(3):219-30.doi: 10.1016/j.ejpain.2008.04.011
54. Pergolizzi J, Aloisi AM, Dahan A, Filitz J, Langford R, Likar R, et al. Current knowledge of buprenorphine and its unique pharmacological profile. Malden, USA: Blackwell Publishing Inc; 2010. p. 428-50.
55. Therapeutic Goods Administration. Australian public assessment report for buprenorphine [cited 2020 16 Jul]. Available from: <https://www.tga.gov.au/sites/default/files/auspar-buprenorphine-161213.pdf>.
56. Vadivelu N, Hines RL. Management of chronic pain in the elderly: focus on transdermal buprenorphine. *Clin Interv Aging*. 2008 [cited 2020 11 Aug]; 3(3):[421-30 p.]^pp.]. Available from: <https://pubmed.ncbi.nlm.nih.gov/18982913>.
57. Böger RH. Renal impairment: a challenge for opioid treatment? The role of buprenorphine. *Palliative medicine*. 2006;20(8_suppl):17-23.doi: 10.1191/0269216306pm1127oa
58. Therapeutic Goods Administration. APO-Fentanyl (Fentanyl) Transdermal drug delivery system. Australian Product Information. 2020 [cited 2020 16 Jul]; p.]^pp.]. Available from: <https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2011-PI-03059-3&d=202007161016933>.
59. Lexicomp. Fentanyl: Drug Information [cited 2021 6 May]. Available from: <https://www.uptodate.com/contents/fentanyl-drug-information>.
60. Insight Centre for AOD Training and Workforce Development, QScript Learning. Tony Hall opioid rotation guidelines [cited 2020 1 Oct]. Available from: <https://youtu.be/ZG-j9FfQsJQ>.

61. Insight Centre for AOD Training and Workforce Development. ROOM to improve? New tools for Routine Opioid Outcome Monitoring for people prescribed opioids for chronic pain- Associate Professor Suzanne Nielsen [cited 2020 22 Oct]. Available from: <https://insight.qld.edu.au/training/room-to-improve-new-tools-for-routing-opioid-outcome-monitoring-for-people-prescribed-opioids-for-chronic-pain/detail>.
62. Insight Centre for AOD Training and Workforce Development, QScript Learning. Tony Hall - Rotation to tramadol and tapentadol [cited 2020 30 Jun]. Available from: <https://youtu.be/Jc1K4ygU9qk>.
63. Insight Centre for AOD Training and Workforce Development, QScript Learning. Example opioid rotation correspondence. Brisbane: State of Queensland (Department of Health); 2020.
64. Insight Centre for AOD Training and Workforce Development, QScript Learning. Tony Hall - Considerations around opioid patches [cited 2020 30 Jun]. Available from: <https://youtu.be/tDHoNSANi2I>.
65. Insight Centre for AOD Training and Workforce Development, QScript Learning. Tony Hall - Educating patients about Norspan® (buprenorphine) patches [cited 2020 30 Jun]. Available from: <https://youtu.be/Hu4un4ikv8g>.
66. Murphy L, Babaei-Rad R, Buna D, Isaac P, Murphy A, Ng K, et al. Guidance on opioid tapering in the context of chronic pain: Evidence, practical advice and frequently asked questions. *Can Pharm J (Ott)*. 2018;151(2):114-20.doi: 10.1177/1715163518754918
67. Schuster M, Bayer O, Heid F, Laufenberg-Feldmann R. Opioid Rotation in Cancer Pain Treatment. *Dtsch Arztebl Int*. 2018;115(9):135-42.doi: 10.3238/arztebl.2018.0135